(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 May 2014 (08.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/071125 A1

(51) **International Patent Classification**:
A61P 35/00 (2006.01) *A61K 31/519* (2006.01)
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)
A61K 45/06 (2006.01)

(21) **International Application Number**:
PCT/US2013/067956

(22) **International Filing Date**:
1 November 2013 (01.11.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
4595/CHE/2012 2 November 2012 (02.11.2012) IN
61/771,812 2 March 2013 (02.03.2013) US

(71) **Applicants**: **TG THERAPEUTICS, INC.** [US/US]; 787 Seventh Avenue, 48th Floor, New York, New York 10019 (US). **RHIZEN PHARMACEUTICALS SA** [CH/CH]; Fritz Courvoisier 40, CH-2300 La Chaux de Fonds (CH). **LFB BIOTECHNOLOGIES S.A.S.** [FR/FR]; 3 Avenue de Tropiques, B.P. 305-Les Ulis, F-91958, Courtaboeuf Cedex (FR).

(72) **Inventors**: **WEISS, Michael**; c/o TG Therapeutics, Inc., 787 Seventh Avenue, 48th Floor, New York, New York 10019 (US). **MISKIN, Hari**; c/o TG Therapeutics, Inc., 787 Seventh Avenue, 48th Floor, New York, New York 10019 (US). **SPORTELLI, Peter**; c/o TG Therapeutics, Inc., 787 Seventh Avenue, 48th Floor, New York, New York 10019 (US). **VAKKALANKA, Swaroop K.V.S.**; c/o Rhizen Pharmaceuticals SA, Fritz Courvoisier 40, La Chaux de Fonds 2300 (IN).

(74) **Agent**: **WILSON, M. Lisa**; Wilson IP Law, 5204 Delafield Ave, Bronx, New York 10471 (US).


(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR

Results



RP 5307 Showed no CD 19 cell depletion at 1000 nM

RP 5307 Showed 1.35% CD20 cell depletion at 1000 nM

FIG. 1

(57) **Abstract**: Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

WO 2014/071125 A1